




The relative strengths and weaknesses of Zentalis Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zentalis Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 106% points. The greatest weakness of Zentalis Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 314%, being 99% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	386,066
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	52,725
Liabilities, Non-Current	40,426
Other Assets	39,572
Other Compr. Net Income	-1,608
Other Expenses	3,913
Other Liabilities	0
Other Net Income	25,504
Other Revenues	67,425
Property and Equipment	4,699
Research and Development	167,768
Selling, General and Administrative Expense	87,115

Output Variable	Value in 1000 USD
Assets	430,337
Liabilities	93,151
Expenses	258,796
Revenues	67,425
Stockholders Equity	337,186
Net Income	-165,867
Comprehensive Net Income	-166,671
BaseVar	438,410
ECR before LimitedLiability	217%
Economic Capital Ratio	314%